Shares of Advaxis Inc. (NASDAQ:ADXS) traded up 1.9% during mid-day trading on Tuesday . The company traded as high as $10.80 and last traded at $10.61, with a volume of 326,539 shares traded. The stock had previously closed at $10.41.

A number of equities analysts have commented on ADXS shares. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Thursday, August 4th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a report on Friday, August 5th. Barclays PLC lifted their price objective on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a report on Thursday, July 7th. Five analysts have rated the stock with a buy rating, Advaxis presently has a consensus rating of “Buy” and a consensus price target of $24.60.

The stock’s market capitalization is $420.75 million. The stock’s 50-day moving average is $12.42 and its 200 day moving average is $9.48.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/advaxis-inc-adxs-trading-1-9-higher.html

In other Advaxis news, Director Richard J. Berman sold 18,000 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the sale, the director now owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Sidransky sold 22,808 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total value of $342,348.08. Following the sale, the director now directly owns 91,759 shares of the company’s stock, valued at approximately $1,377,302.59. The disclosure for this sale can be found here. Company insiders own 4.56% of the company’s stock.

A number of large investors have recently made changes to their positions in ADXS. Sarissa Capital Management LP bought a new stake in shares of Advaxis during the second quarter worth about $4,853,000. Marshall Wace LLP bought a new stake in shares of Advaxis during the second quarter worth about $2,213,000. Parametric Portfolio Associates LLC raised its position in shares of Advaxis by 163.9% in the second quarter. Parametric Portfolio Associates LLC now owns 62,424 shares of the biotechnology company’s stock worth $505,000 after buying an additional 38,769 shares during the period. Allianz Asset Management AG raised its position in shares of Advaxis by 60.5% in the second quarter. Allianz Asset Management AG now owns 185,813 shares of the biotechnology company’s stock worth $1,503,000 after buying an additional 70,045 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of Advaxis during the second quarter worth approximately $229,000. 55.86% of the stock is owned by hedge funds and other institutional investors.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

5 Day Chart for NASDAQ:ADXS

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.